Tumor News and Research

RSS

Personalized therapy shows improved response in cancer patients

In a meta-analysis of hundreds of clinical trials involving thousands of patients, researchers at University of California San Diego School of Medicine report that therapeutic approaches using precision medicine, which emphasizes the use of individual genetics to refine cancer treatment, showed improved response and longer periods of disease remission, even in phase I trials.

7 Jun 2016

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute.

7 Jun 2016

New study identifies PDGFRα as key molecule for HCMV viral entry

A publication in the scientific journal Nature Microbiology identifies PDGFRα as the receptor for the trimeric gHgLgO complex of Human cytomegalovirus (HCMV).

7 Jun 2016

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.

7 Jun 2016

Innovative mouse model could provide new strategy to arrest growth of pancreatic cancer

Pancreatic ductal adenocarcinoma, the most common of pancreatic cancers, is extraordinarily lethal, with a 5-year survival rate of just 6 percent. Chemotherapy treatments are poorly effective, in part due to a high degree of drug-resistance to currently used regimens.

7 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Advances in precision diagnostics aid accurate detection of CNS tumors

Thanks to new methods of precision diagnostics, such as DNA sequencing and epigenetic analyses, it is becoming increasingly possible to identify specific central nervous system (CNS) tumors accurately and to provide targeted treatment. The Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital is one of the top centers in the world for diagnosing and treating this type of tumor.

6 Jun 2016

Personlized exercise pattern may help reduce neuropathic symptoms of chemotherapy

Researchers at the University of Rochester Wilmot Cancer Institute discovered something simple and inexpensive to reduce neuropathy in hands and feet due to chemotherapy--exercise.

6 Jun 2016

Giving chemotherapy after radiotherapy delays rare brain tumour growth

GIVING chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years from 44 per cent to 56 per cent.

6 Jun 2016

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients.

6 Jun 2016

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found.

6 Jun 2016

Gene dysregulation makes immune therapies less effective against metastatic melanoma

Patients who don't respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to study results presented at the annual meeting of the American Society for Clinical Oncology on June 4 in Chicago.

6 Jun 2016

Understanding chemotherapy cost differences could help patients in making informed decisions

Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. Understanding cost differences should help guide informed discussions between patients and physicians when considering chemotherapy options.

6 Jun 2016

Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

For seven months, three-year-old Emil Abbasov underwent chemotherapy to fight the tangerine-sized, cancerous tumor growing in his abdomen. But each time, the tumor resisted harder. Each time, he felt more side effects.

6 Jun 2016

MBC Project engages patients directly to accelerate cancer research

A crowd-sourcing strategy aimed at accelerating research into metastatic breast cancer has connected advocacy groups, social media, and a dedicated web site to register more than 2,000 patients from all 50 states in its first seven months, say researchers from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

6 Jun 2016

Gene alterations in WNT pathway may increase CRC risk in younger patients

While increased screening continues to drive down overall colorectal cancer rates, the rate of colorectal cancer in patients under age 50 is increasing, and the disease is commonly more aggressive in these young patients.

6 Jun 2016

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial to be presented June 5 at the annual meeting of the American Society for Clinical Oncology.

6 Jun 2016

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed.

4 Jun 2016

Tumor News and Research

Personalized therapy shows improved response in cancer patients

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

New study identifies PDGFRα as key molecule for HCMV viral entry

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Innovative mouse model could provide new strategy to arrest growth of pancreatic cancer

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Advances in precision diagnostics aid accurate detection of CNS tumors

Personlized exercise pattern may help reduce neuropathic symptoms of chemotherapy

Giving chemotherapy after radiotherapy delays rare brain tumour growth

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Gene dysregulation makes immune therapies less effective against metastatic melanoma

Understanding chemotherapy cost differences could help patients in making informed decisions

Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

MBC Project engages patients directly to accelerate cancer research

Gene alterations in WNT pathway may increase CRC risk in younger patients

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News